当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
YESCARTA, axicabtagene ciloleucel
药品名称
YESCARTA, axicabtagene ciloleucel
承诺描述
A post-marketing, prospective, multi-center, observational study to assess the long-term safety of axicabtagene ciloleucel and the risk of secondary malignancies occurring after treatment with axicabtagene ciloleucel. The study will include at least 1500 adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy; the enrolled patients will be followed for 15 years after the product administration.